Increased vascular endothelial growth factor (VEGF) expression in osteosarcoma correlates with a poor outcome. We conducted a phase II trial to evaluate the feasibility and efficacy of combining bevacizumab, a monoclonal antibody against VEGF, with methotrexate, doxorubicin and cisplatin (MAP) in patients with localized osteosarcoma. Eligible patients received two courses of MAP chemotherapy before definitive surgery at week 10. Bevacizumab (15 mg/kg) was administered 3 days before starting chemotherapy then on day 1 of weeks 3 and 5 of chemotherapy. After surgery, patients received MAP for a total of 29 weeks; bevacizumab was added every 2 or 3 weeks on day 1 of chemotherapy at least 5 weeks after surgery. Group sequential monitoring rules were used to monitor for unacceptable bevacizumab-related targeted toxicity (grade 4 hypertension, proteinuria or bleeding, grade 3 or 4 thrombosis/embolism, and grade 2-4 major wound complications). Thirty-one patients (median age 12.8 years) with localized osteosarcoma were enrolled. No unacceptable targeted toxicities were observed except for wound complications (9 minor and 6 major), which occurred in 15 patients; none required removal of prosthetic hardware or amputation. The estimated 4-year event-free survival (EFS) rate and overall survival rate were 57.5 6 10.0% and 83.4 6 7.8%, respectively. Eight (28%) of 29 evaluable patients had good histologic response (<5% viable tumor) to preoperative chemotherapy. The addition of bevacizumab to MAP for localized osteosarcoma is feasible but frequent wound complications are encountered. The observed histologic response and EFS do not support further evaluation of bevacizumab in osteosarcoma.
Osteosarcoma is the most common malignant bone tumor in children and adolescents. Approximately 20% of patients will have clinically detectable metastatic disease, mostly to lung and bone, at the time of diagnosis. 1 The survival for patients with newly diagnosed localized osteosarcoma is approximately 70% compared with 30% for patients with metastatic disease. [2] [3] [4] Therapy consists of aggressive surgery and multiagent chemotherapy, which usually includes a standard regimen of high-dose methotrexate, doxorubicin, and cisplatin (MAP). [4] [5] [6] [7] The use of other drugs such as ifosfamide and interferon or the intensification of active drugs (e.g., doxorubicin) has not improved patient outcomes since the 1990s. 4, [7] [8] [9] Thus, the outcome of patients with localized osteosarcoma appears to have reached a plateau over the past three decades with no added benefit from intensifying or adding new cytotoxic chemotherapy, underscoring the need for novel therapeutic strategies. Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis, which is essential for tumor growth and metastasis. 10, 11 Preclinical xenograft models demonstrate that targeting VEGF in osteosarcoma results in growth inhibition. 12, 13 Furthermore, increased serum levels and protein expression of VEGF in tumor specimens have been correlated with worse outcome in patients with osteosarcoma, suggesting that VEGF is a potential therapeutic target in this tumor type. [14] [15] [16] Bevacizumab, a monoclonal antibody against VEGF, combined with cytotoxic chemotherapy has significantly improved the outcomes in adults with a variety of cancers. [17] [18] [19] The addition of bevacizumab not only inhibits angiogenesis but also is thought to improve the delivery of chemotherapy by altering or "normalizing" the tumor vasculature and decreasing elevated interstitial pressure in tumors. 20 Adverse events commonly related to bevacizumab as a single agent or in combination with chemotherapy have been limited to mild to moderate hypertension, proteinuria, bleeding, and thrombosis. 21 Because neovascularization plays a critical role in wound healing, the potential for bevacizumab to affect post-operative healing is a concern that has not been systematically studied in patients undergoing resection of bone tumors. Based on the rationale above, we wished to investigate whether targeting angiogenesis may be a novel therapeutic strategy for osteosarcoma. Therefore What's new? Increased expression of vascular endothelial growth factor (VEGF) is associated with a poor prognosis in patients with osteosarcoma. In this study, the authors asked whether the anti-VEGF drug bevacizumab might enhance standard chemotherapy and improve patient outcomes. Unfortunately, despite promising preclinical studies, the answer was no. The bevacizumab also increased the risk of serious wound-healing complications. The authors conclude that further evaluation of bevacizumab in osteosarcoma is therefore not warranted. However, the study provides important data regarding the use of antiangiogenic agents when surgical resection of a primary bone tumor is required.
Treatment
The treatment schema is shown in Figure 1 . Bevacizumab was administered 3 days before the first dose of chemotherapy at week 0 to characterize the single-dose single agent pharmacokinetics of the drug in children 22 and to assess the effect of bevacizumab alone on the tumor vasculature using dynamic contrast-enhanced MRI 23 , as previously reported. All subsequent doses of bevacizumab were given on day 1 of chemotherapy. Two weeks after definitive surgery for primary tumor removal, chemotherapy was resumed once adequate wound healing was observed. Due to concerns about potential effects of bevacizumab on wound healing, the study was designed such that bevacizumab was not administered for at least 5 weeks before and for at least 5 weeks after definitive surgery. Granulocyte colony-stimulating factor (either filgrastim or pegfilgrastim) was administered after each cycle of chemotherapy that included doxorubicin or cisplatin. At the time of definitive surgery, the bone resection margins were determined to be a minimum of 1.5 cm proximal (or distal) to the known extent of intraosseous (intracortical) involvement by the tumor as defined by the scanograms and MRI at the time of initial diagnosis.
Evaluations, toxicity grading and response criteria
Evaluations at baseline, during and after completion of therapy are outlined in Appendix. All adverse events except for wound complications were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
24 Given the limitations of the CTCAE criteria for grading wound complications, we developed more comprehensive criteria for grading these adverse events. We categorized wound complications as minor or major based on whether the wound was superficial (above the fascia) or deep (below the fascia), respectively. Minor wound complications were graded as follows: Grade 1, epidermolysis or marginal wound necrosis requiring only routine wound care; Grade 2, wound dehiscence requiring advanced wound care including vacuumassisted closure; Grade 3, wound infection/dehiscence treated conservatively including antibiotics; Grade 4, wound dehiscence requiring surgical closure and Grade 5, wound infection/dehiscence requiring debridement and primary or secondary wound closure. Major wound complications were graded as follows: Grade 1, culture proven infection treated with antibiotics without surgical intervention; Grade 2, infection/dehiscence requiring debridement and primary or secondary wound closure; Grade 3, infection requiring removal of hardware with limb salvage and Grade 4, infection requiring amputation.
Radiologic response of the primary tumor to neoadjuvant therapy (at weeks 5 and 10) was evaluated using threedimensional volumetric measurements using an elliptical model (0.5 times the product of the three largest perpendicular diameters). Disease assessment was classified as: complete response (CR), complete disappearance of tumor; partial response (PR), at least 50% decrease in volume compared with the measurement obtained at study entry; progressive disease (PD), at least 25% increase in tumor volume compared with the smallest volume obtained since the beginning of therapy; and stable disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as a reference the smallest disease volume since treatment started.
Tumor necrosis following preoperative chemotherapy was classified using a modified Huvos grading system 7,25 as follows: Grade I, no response to therapy; Grade IIA, >50% viable tumor; Grade IIB, 5-50% viable tumor; Grade III, < 5% viable tumor and Grade IV, no viable tumor.
Pharmacokinetics
Bevacizumab pharmacokinetic studies were performed at weeks 0, 3 and 5. The sampling strategy, sample analysis and development of the population pharmacokinetic model for bevacizumab have been described previously. 22 Bevacizumab concentration-time data were fit to a two-compartment model with first order elimination from the central compartment. Bevacizumab exposure [area under curve (AUC)] from 
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the first dose (week 0) to time of methotrexate administration was estimated for each patient using a nonlinear mixed effects model in NONMEM (version 7.3; ICON solutions, Hanover, MD), a software package used for population pharmacokinetic modeling. Methotrexate pharmacokinetic studies were performed in all patients for clinical monitoring purposes with samples routinely collected at the end of infusion (4 hr) and 24, 48 and 72 hrs post infusion. A twocompartment model with first order elimination using ADAPT II (Biomedical Simulations Resource, University of Southern California) was fit to plasma methotrexate concentrations, which were analyzed by a fluorescence polarization immunoassay (TDx System; Abbott Laboratories, Abbott Park, IL). Methotrexate systemic clearance (CL t ) was calculated based on the model-predicted elimination rate constant (k e ) and volume of distribution of the central compartment (V c ).
Study design and statistical methods
A historical control design was adopted to assess the effect EFS of adding bevacizumab to MAP chemotherapy, where the MAP chemotherapy arm of the INT0133 study 7 served as the historical control. The sample size was determined to show an increase in 3-year EFS from 70 to 85% based on the method of Dixon and Simon 26 with one-sided significance level 5% and power of 80%. EFS was defined as the interval from the date on study to the date of first event (relapse or progressive disease, second malignancy and death from any cause) or last follow-up. Overall survival (OS) was defined as the interval from the date on study to the date of death from any cause or last follow-up. EFS and OS were estimated using the method of Kaplan and Meier. Group sequential stopping rule was used for monitoring unacceptable toxicities related to the addition of bevacizumab to MAP chemotherapy. Unacceptable toxicities were defined as grade 4 hypertension, proteinuria or bleeding, grade 3 or 4 thrombosis/embolism (excluding catheter-related thrombosis) and grade 2, 3 or 4 major wound complications. The study closed early due to slow accrual. Fisher's exact test was used to assess association between imaging response and histologic response. The Wilcoxon rank sum test was used to compare therapy completion times between patients with and without wound complications. Logistic regression was used to examine the association between the presence or absence of a wound complication with time to complete therapy. For the purpose of this analysis, the time to complete therapy was the date of the last dose of chemotherapy. Cox regression was used to assess associations between outcome, development of wound complication and time to complete therapy. To investigate the effect of bevacizumab on methotrexate disposition, the cumulative bevacizumab exposure before methotrexate administration for each course was estimated and analyzed with respect to the methotrexate CL t .
Results

Patient characteristics
Between June 2008 and May 2012, 31 patients were enrolled. Patient characteristics are summarized in Table 1 and Appendix (Table 1) . Surgical resection of the primary tumor was performed after planned chemotherapy in 29 patients. The type of surgery performed included limb-salvage surgery (i.e., en-bloc resection followed by reconstruction with endoprosthesis, allograft and allograft prosthetic composite) (N 5 20), amputation (N 5 8) and hemimandibulectomy (N 5 1). Two patients did not undergo surgery at week 10 because of progressive disease at week 5 in one patient and patient refusal in the other.
Toxicity
The most common grade 3 or 4 toxicities were those typically observed with MAP chemotherapy, namely elevated liver transaminases and myelosuppression (Table 2) . No unacceptable non-wound related targeted toxicities [i.e., grade 4 hypertension, proteinuria or bleeding and grade 3 or 4 thrombosis/embolism (excluding catheter-related thrombosis)] related to bevacizumab were observed. Common grade 1 or 2 toxicities during therapy that may be attributed to bevacizumab included epistaxis (74% of patients), proteinuria (68%), hypertension (39%) and left ventricular dysfunction (13%). With the exception of fever in one patient during the first infusion of bevacizumab, no other infusion-related side effects were observed. None of the interim stopping boundaries for toxicity were met, and there were no deaths due to toxicity. Growth plate abnormalities as assessed by radiograph of the unaffected knee were not observed. The planned interval to resume chemotherapy and bevacizumab after surgery (week 10) as set by protocol was 14 days and 35 days, respectively (Fig. 1) . The actual median interval to resume chemotherapy (N 5 27) and bevacizumab (N 5 22) after surgery was 16 days (range, 13-51 days) and 40 days (range, 34-151 days), respectively. Fifteen patients (15/29, 52%) had wound complications, 9 minor and 6 major, following definitive surgery (Table 3) . No patient experienced significant bleeding or thrombosis nor did any patient require revision of the prosthesis or amputation during the postoperative period. Although protocol specified stopping rules for wound complications were not met, poor wound healing prohibited resuming bevacizumab in five patients and required holding at least one of the six planned doses in 10 patients after definitive surgery. Wound complications/delayed wound healing was the primary reason for omitting 52 (21.3%) of the 244 planned doses of bevacizumab. Other reasons for omitting bevacizumab doses included thoracotomy (2 doses) and bone fracture (1 dose).
Response and outcome
Two patients were excluded from the assessment of histologic response: the patient who refused surgery at the protocolspecified time point and another patient who had a cystic lesion that was fluid filled in the center and had viable tumor cells at the rim. Assessment of histologic response in the latter patient was felt to be inaccurate. Of the remaining 29 patients, 8 (28%) had a good histologic response (Huvos Grade III, < 5% viable tumor) to preoperative chemotherapy.
Of the 28 patients who had an MRI of the primary tumor to assess tumor imaging response at week 5, 27 had SD and 1 had PD. Of the 30 patients who underwent an MRI at week 10, 4 had PR, 25 had SD and 1 was not evaluable because of a pathologic fracture that had developed on therapy. The association between histologic response and imaging The median duration of follow-up from the time of study enrollment was 4.8 years (range, 1.7 years-7.0 years) for the 24 survivors. All survivors were seen or contacted within 18.4 months from the time of analysis. Thirteen patients have experienced recurrence or progression of disease as a first event (1 local, 11 distant and 1 local and distant); 6 of these patients died of disease. One additional patient developed a second malignancy (acute myeloid leukemia) and subsequently died. Six patients were removed from protocol therapy for reasons other than recurrence or progressive disease; three because the treating physician determined that it was in the best interest of the patient, one for non-adherence to protocol therapy (refused surgery at week 10), one because of family/patient request and one due to development of second malignancy. The 4-year estimates for EFS and OS for all patients were 57.5 6 10.0% and 83.4 6 7.8%, respectively.
We assessed whether wound complications after definitive surgery resulted in delay in therapy and whether wound complications (minor, major or both) had an impact on EFS and OS. Using logistic regression analysis, any wound complication (major and minor) after surgery was significantly associated with longer time to complete therapy [median 274 days (range, 235-331 days) with wound complications vs. median 240 days (range, 84-278 days) without wound complication (p 5 0.0118)]. However, the development of wound complications after definitive surgery did not have a significant effect on EFS (p 5 0.11, hazard ratio 5 2.66). Hazard ratio for OS could not be determined because no deaths were observed in patients who developed wound complications.
The 4-year EFS estimates for patients without and with wound complications were 47.6 6 14.1% and 73.3 6 12.0%, respectively (p 5 0.0964, log-rank test). The 4-year OS estimates for patients without and with wound complications were 69.6 6 12.8% and 100 6 0.0%, respectively (p 5 0.0042, log rank test).
Pharmacokinetics
Serial bevacizumab and methotrexate pharmacokinetic studies were performed in 20 patients. A summary of the bevacizumab exposures and methotrexate clearance values by treatment week is provided in Table 4 . Cumulative bevacizumab exposures at weeks 3 and 4 were not significantly correlated with methotrexate CL t at weeks 3 and 4 ( Figs. 2a and 2b) . However, cumulative bevacizumab exposures at weeks 8 and 9 were negatively correlated with methotrexate CL t at weeks 8 (R 2 5 0.38) and 9 (R 2 5 0.46) (Figs. 2c and 2d) . 
Discussion
This clinical trial investigated the feasibility and safety of bevacizumab in combination with standard MAP chemotherapy in newly diagnosed patients with localized, resectable high-grade osteosarcoma. The observed bevacizumab-related systemic toxicities were relatively mild in severity, but major and minor wound healing complications were seen in approximately half of the patients following definitive surgery and resulted in discontinuation or omission of 21% of the planned doses of bevacizumab. No grade 4 hypertension, proteinuria or bleeding, nor grade 3 or 4 thrombosis/embolism potentially related to the addition of bevacizumab were observed. Wound healing is a complex process 27 that includes a neovascularization phase similar to the one that supports tumor growth with VEGF and VEGF receptors as key regulators. [28] [29] [30] Issues related to wound healing have been a concern in patients receiving bevacizumab for several tumor types with variable recommendations for patients undergoing surgery. [31] [32] [33] [34] However, the most prominent effect of bevacizumab on wound healing seems to occur when it is administered during or before surgery. This is the basis for the recommendation in the prescribing label of bevacizumab to discontinue bevacizumab at least 28 days before elective surgery and to resume bevacizumab at least 28 days post surgery, once the surgical wound is fully healed. A novel finding from the present study that we previously reported is that bevacizumab exposure (i.e., area under the concentration-time curve, AUC) before surgery was associated with increased risk of major wound healing complications after surgery.
22
Our study is the first to explore the incidence of wound healing complications after limb salvage or amputation in patients receiving bevacizumab and chemotherapy. In planning the study, we realized that the CTC grading criteria were inadequate to properly define wound complications. Furthermore, the rate of wound complications in patients undergoing these procedures who are receiving chemotherapy There was no significant correlation between bevacizumab cumulative exposures and methotrexate CL t at weeks 3 (a) and 4 (b); however, at weeks 8 (c) and 9 (d), there was a significant negative correlation between methotrexate CL t and bevacizumab systemic exposure.
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alone is difficult to discern from the literature. Therefore, we established a comprehensive grading system and retrospectively applied this grading system to our preceding clinical trial (OS99). 35 This allowed us to establish an estimate of an expected rate of wound healing complications for developing the stopping rules as outlined. The stopping rules were not met; however, there are limitations to this approach. First, the prevalence of wound healing complications in OS99 was determined retrospectively. Second, the chemotherapy regimen used in the OS99 trial (ifosfamide, doxorubicin and carboplatin) was different from the MAP chemotherapy used in the present trial and could potentially affect the incidence of wound healing. Third, our stopping rules did not take into consideration the impact of delayed wound healing on the dose intensity of bevacizumab and ability to deliver chemotherapy on time. In our study, patients with wound healing complications had a longer time to complete therapy than those without wound complications; although, their outcomes were not significantly worse than those without wound complications. In fact, our data actually shows a trend toward a better outcome in patients with wound complications. This latter finding is intriguing but should be interpreted with caution due to the small number of patients.
The addition of bevacizumab did not improve the percentage of patients with good histologic response to preoperative chemotherapy, a strong predictor of outcome in osteosarcoma. 7, 36, 37 The observed good histologic response (< 5% viable tumor) to two courses of MAP chemotherapy alone was 43% in the INT0133 study, 7 versus 28% to two courses of MAP with bevacizumab in our trial. Furthermore, compared with outcomes reported for localized osteosarcoma, no apparent improvement in EFS or OS was observed with the addition of bevacizumab to MAP chemotherapy in our small cohort of patients. 4, 6, 35 Other efforts to improve patient outcomes have been largely unsuccessful. [7] [8] [9] 38 It remains to be seen whether novel therapeutic approaches such as immunotherapy will be beneficial in this population. 38 Consistent with prior reports, we found no significant correlation between 3D anatomic measurements of primary tumor on MRI and histologic response. [39] [40] [41] This is most likely because the extent of MR signal abnormality in the affected bone typically represents a combination of viable tumor, partially treated tumor, necrosis and bland edema. Furthermore the signal abnormality has irregular contours that cannot be accurately measured by simple 1D, 2D or 3D measurements. This finding underscores the urgent need for more robust methods of assessing bone tumor response to neoadjuvant therapy. Metabolic imaging modalities such as dynamic enhanced MRI and positron emission tomography may provide more accurate measurements of tumor response. 23 The primary mechanism of elimination of methotrexate is by the kidney. Because VEGF targeting agents may cause renal vascular endothelial dysfunction and glomerular epithelial cell dysregulation, 42 we sought to investigate the effect of bevacizumab on renal clearance of methotrexate (CL t ) by analyzing the effect of cumulative bevacizumab exposure effect on methotrexate pharmacokinetics. We found no correlation between bevacizumab cumulative exposures and methotrexate CL t at weeks 3 and 4 ( Figs. 2a and 2b ). This suggests no immediate or acute effect of bevacizumab on methotrexate disposition since bevacizumab is given immediately before methotrexate on week 3. Moreover, since we did not observe an effect on week 4 methotrexate clearance, it is unlikely that a delayed effect will be observed after a dose of bevacizumab. However, after the third bevacizumab dose, the methotrexate clearances decreased in relation to the bevacizumab systemic exposure (Figs. 2c and 2d ). This suggests patients with greater overall bevacizumab exposures are at risk of lower methotrexate CL t . However, after the third dose of bevacizumab, our patients received additional doses of nephrotoxic chemotherapy (i.e., cisplatin), which has been previously shown to decrease methotrexate CL t . 43 Therefore, the observed decrease in methotrexate CL t at weeks 8 and 9 may be attributed to a combination of factors including bevacizumab exposures suggesting additional care should be taken when administering bevacizumab in these clinical situations.
In summary, the addition of bevacizumab to MAP chemotherapy was tolerated with no additional toxicity except for frequent wound complications requiring debridement and primary or secondary wound closure. In addition, this combination did not appear to improve histologic response or outcome for patients with localized osteosarcoma. Although limited by the small number of patients, our findings do not suggest that further evaluation of bevacizumab in patients with osteosarcoma is warranted. Our study highlights that careful monitoring of wound healing complications is needed when considering other antiangiogenic agents (e.g., tyrosine kinase inhibitors such as sorafenib 44 ) for osteosarcoma treatment.
